about
Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)Primary care referrals of patients with potentially serious diseases to the emergency department or a quick diagnosis unit: a cross-sectional retrospective studyStructured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Update on antiretroviral treatment during primary HIV infection.Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.When will biomedical research enter the 21st century? A 'young' perspective.Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.A case of Mycoplasma hominis disseminated infection in a human immunodeficiency virus-1-infected pregnant woman with hypogammaglobulinemia.HIV treatment outcomes in Europe and North America: what can we learn from the differences?Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patientPrevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort studyEpidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study
P50
Q28547790-3867AA68-A64A-4C1F-8E3D-CEB80F12CBE6Q33612588-31C9F566-7AAA-42EF-9B9B-BA475713097DQ35862206-C366BE24-9415-455E-A05C-C99EDFEB3100Q37069837-101B0E64-1268-4449-85CC-D13424F6E018Q38209874-35214930-AC24-4EC1-9175-0F4B6F5AD38EQ38383280-4A5E3EC4-A4DC-459B-9288-D6A328BBEE6FQ38538043-27CB216D-579A-4D46-A6B2-7293F831C50FQ39812252-C00E9F2D-AB77-4C23-9E44-3BAB2DFF8A7BQ40118949-DAA22CD3-735D-4EDE-B95D-8D717E6C0966Q40436387-485ADEA1-6E0D-44B2-BEF8-A1284BDFAD0CQ40541471-937E88F7-DF36-446A-ACC0-7FAB2930D67DQ45343343-9B153430-3FC5-481E-B187-AF46C9F88779Q51846375-AAFAB061-46EF-42FB-8604-3BF0E327E848Q59531068-84769DE2-8F1C-493F-B8CA-91D0799D7DA5Q92544559-264ACC8F-03FF-419D-BC65-A7FC2FEC8A81Q93345966-35792BB7-F13C-4476-A661-FD15C35B9293
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
David Nicolás
@ast
David Nicolás
@en
David Nicolás
@es
David Nicolás
@nl
David Nicolás
@sl
type
label
David Nicolás
@ast
David Nicolás
@en
David Nicolás
@es
David Nicolás
@nl
David Nicolás
@sl
prefLabel
David Nicolás
@ast
David Nicolás
@en
David Nicolás
@es
David Nicolás
@nl
David Nicolás
@sl
P106
P21
P214
4709148947767254950005
P31
P496
0000-0002-1968-5287
P735
P7859
viaf-4709148947767254950005